46 related articles for article (PubMed ID: 11676865)
1. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract][Full Text] [Related]
2. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
[TBL] [Abstract][Full Text] [Related]
3. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Vassetzky YS; Alghisi GC; Gasser SM
Bioessays; 1995 Sep; 17(9):767-74. PubMed ID: 8763829
[TBL] [Abstract][Full Text] [Related]
5. Using yeast to study resistance to topoisomerase II-targeting drugs.
Nitiss JL
Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
[TBL] [Abstract][Full Text] [Related]
6. Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Oct; 92(10):1133-7. PubMed ID: 11676865
[TBL] [Abstract][Full Text] [Related]
7. [Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Matsumoto Y; Morisaki K; Kunishio K; Nagao S; Takano H; Fojo T
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1145-9. PubMed ID: 9679576
[TBL] [Abstract][Full Text] [Related]
8. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
9. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
10. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729
[TBL] [Abstract][Full Text] [Related]
11. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
